MediWound Ltd. (NASDAQ:MDWD) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, August 2nd.
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
A number of other research firms have also recently weighed in on MDWD. Aegis reissued a “buy” rating and issued a $11.00 price target on shares of MediWound in a report on Thursday, May 25th. SunTrust Banks, Inc. reiterated a “buy” rating on shares of MediWound in a research note on Monday, June 26th. Finally, Oppenheimer Holdings, Inc. set a $10.00 target price on MediWound and gave the company a “buy” rating in a research note on Monday, May 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $10.19.
MediWound (MDWD) opened at 6.60 on Wednesday. The company has a 50-day moving average price of $6.87 and a 200 day moving average price of $6.46. MediWound has a 1-year low of $4.25 and a 1-year high of $8.58. The firm’s market capitalization is $144.90 million.
MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The business’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.34) earnings per share. Analysts expect that MediWound will post ($0.81) earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares during the period. Wells Fargo & Company MN increased its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares during the period. Finally, Wellington Management Group LLP increased its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the period. Hedge funds and other institutional investors own 27.32% of the company’s stock.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about MediWound Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MediWound Ltd. and related companies.